Estrogen receptor corepressors -- a role in human breast cancer?
- PMID: 14713265
- DOI: 10.1677/erc.0.0100517
Estrogen receptor corepressors -- a role in human breast cancer?
Abstract
Estrogen receptor alpha (ERalpha) has an established role in promoting breast cancer. Transcriptional activation by ERalpha is a complex and multistep process, and it is influenced by coactivator and corepressor proteins that can either positively or negatively modulate ERalpha-mediated transcriptional activity. Corepressors are proposed to provide a counterbalance to the estrogen-induced transactivation, and represent a potential mechanism employed by the cell to regulate hormonal responses. In this review, we present evidence from tissue culture, animal and clinical studies, supporting the hypothesis that corepressors are crucial regulators of ERalpha-mediated action, and that their loss could promote breast cancer development and resistance to endocrine therapy. We propose that ERalpha corepressors play an important biological role by controlling the magnitude of the estrogen response, mediating antiestrogen inhibition of ERalpha, repressing DNA-bound ERalpha in the absence of the ligand, and conferring active repression of ERalpha-downregulated genes. Different ERalpha corepressors regulate steroid receptor activity through a variety of mechanisms, including formation of multiprotein complexes that are able to affect chromatin remodeling, histone deacetylation, or basal transcription. Other mechanisms include competition with coactivators, interference with DNA binding and ERalpha homodimerization, alteration of ERalpha stability, sequestration of ERalpha in the cytoplasm, and effects on RNA processing. Most ERalpha corepressors can control the receptor's activity through more than one mechanism, and it is possible that the synergy between different pathways cooperates to fully inhibit ERalpha transcriptional activity, and create an integrated response to a variety of different cellular signaling pathways. We will discuss the role of corepressors in tumor suppression and the link they might present between ERalpha regulation and DNA repair. Finally, we will discuss major challenges in the field and speculate on the exciting findings that await us in the next few years.
Similar articles
-
Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.J Biol Chem. 2003 Jul 18;278(29):26704-14. doi: 10.1074/jbc.M301031200. Epub 2003 May 8. J Biol Chem. 2003. PMID: 12738788
-
Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.Mol Endocrinol. 2005 Jun;19(6):1543-54. doi: 10.1210/me.2004-0395. Epub 2005 Mar 31. Mol Endocrinol. 2005. PMID: 15802375
-
Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.J Mol Endocrinol. 2004 Oct;33(2):387-410. doi: 10.1677/jme.1.01541. J Mol Endocrinol. 2004. PMID: 15525597
-
Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.Mol Endocrinol. 2016 Sep;30(9):965-76. doi: 10.1210/me.2016-1072. Epub 2016 Jul 20. Mol Endocrinol. 2016. PMID: 27581354 Free PMC article. Review.
-
Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. doi: 10.1016/s0960-0760(00)00104-7. J Steroid Biochem Mol Biol. 2000. PMID: 11162936 Review.
Cited by
-
Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.Acta Pharmacol Sin. 2015 Jan;36(1):24-31. doi: 10.1038/aps.2014.123. Epub 2014 Dec 15. Acta Pharmacol Sin. 2015. PMID: 25500870 Free PMC article. Review.
-
Tamoxifen Action in ER-Negative Breast Cancer.Sign Transduct Insights. 2016 Feb 10;5:1-7. doi: 10.4137/STI.S29901. Sign Transduct Insights. 2016. PMID: 26989346 Free PMC article.
-
Epigenetic targeting in breast cancer: therapeutic impact and future direction.Drug News Perspect. 2009 Sep;22(7):369-81. doi: 10.1358/dnp.2009.22.7.1405072. Drug News Perspect. 2009. PMID: 19890494 Free PMC article. Review.
-
Temporal expression of Pelp1 during proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells.PLoS One. 2013 Oct 16;8(10):e75477. doi: 10.1371/journal.pone.0075477. eCollection 2013. PLoS One. 2013. PMID: 24146754 Free PMC article.
-
Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.Hum Pathol. 2008 Apr;39(4):616-22. doi: 10.1016/j.humpath.2007.09.008. Epub 2008 Mar 4. Hum Pathol. 2008. PMID: 18289639 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical